UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

fool.com ·3h ago

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Read the original at fool.com →

More in Finance & Markets

TAT Technologies GAAP EPS of $0.58 beats by $0.19, revenue of $55.56M beats by $2.72M

3h ago ·seekingalpha.com

Premarket movers: Estee Lauder, Rivian rise premarket; Check Point falls

3h ago ·investing.com

Samsung Tops Africa Smartphone Market for First Time After 31 Years

Samsung Electronics reached the number one spot in smartphone market share for the first time in 31 years since entering the African mobile phone market in 1995.

Samsung Electronics claims top spot in Africa's smartphone market for first time in 31 years.
Samsung's Galaxy A series priced around $200 appeals to Africa's diverse income brackets.
Installment payment system via partnerships with local firms boosts sales by 34.8%.

3h ago ·businesskorea.co.kr

MTN Ghana’s revenue rises 33.5% as digital services expand

MTN Ghana recorded a 33.5% rise in service revenue to GHS23.2B for 9M 2026, spurred by rapid adoption of mobile data, digital services, and mobile money. Profit after tax jumped 43% to GHS7.8B.

3h ago ·techcabal.com

Full House Resorts is downgraded by Texas Capital amid the challenging high-yield market

3h ago ·seekingalpha.com

CME vs. SoFi Technologies: Which Financial Stock Is a Better Buy for 2027?

CME boasts a fortress balance sheet and a 62% net margin, while SoFi is burning cash but growing revenue 28.8% annually, a classic stability-versus-growth showdown.

3h ago ·fool.com